Beta Bionics (NASDAQ:BBNX) Shares Down 8% – Should You Sell?

Beta Bionics, Inc. (NASDAQ:BBNX) fell 8% on Friday . The company traded as low as $13.16 and last traded at $13.1330. 334,288 shares traded hands during trading, a decline of 70% from the average daily volume of 1,129,826 shares. The stock had previously closed at $14.27.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BBNX. Stifel Nicolaus dropped their price target on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Truist Financial lifted their price objective on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Bank of America dropped their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. UBS Group began coverage on Beta Bionics in a research note on Tuesday. They issued a “buy” rating and a $22.00 target price on the stock. Finally, Leerink Partners reduced their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.10.

Beta Bionics Price Performance

The company has a market cap of $590.94 million, a P/E ratio of -8.05 and a beta of 3.04. The company’s 50-day moving average is $14.97 and its two-hundred day moving average is $13.22.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 25.65% and a negative net margin of 61.31%.The business had revenue of $32.01 million for the quarter. Equities research analysts anticipate that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Insider Transactions at Beta Bionics

In related news, insider Steven Jon Russell sold 4,222 shares of Beta Bionics stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $53,239.42. Following the completion of the sale, the insider directly owned 173,849 shares in the company, valued at approximately $2,192,235.89. This trade represents a 2.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 6,676 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $84,184.36. Following the completion of the transaction, the chief financial officer directly owned 166,053 shares of the company’s stock, valued at approximately $2,093,928.33. This trade represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 40,351 shares of company stock valued at $553,961. Insiders own 5.30% of the company’s stock.

Institutional Trading of Beta Bionics

A number of institutional investors have recently made changes to their positions in BBNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Beta Bionics during the 1st quarter valued at about $95,000. Goldman Sachs Group Inc. bought a new position in Beta Bionics during the first quarter valued at approximately $715,000. Woodline Partners LP bought a new position in Beta Bionics during the first quarter valued at approximately $1,530,000. Strs Ohio purchased a new stake in Beta Bionics in the first quarter worth approximately $29,000. Finally, Rhumbline Advisers purchased a new stake in Beta Bionics in the first quarter worth approximately $158,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.